Covered recipient · General Payments record
BOB GENG
Allopathic & Osteopathic Physicians Allergy & Immunology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$565,906.48
553 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $379,128.40 | 106 |
| Travel and Lodging | $108,337.73 | 156 |
| Consulting Fee | $51,314.74 | 21 |
| Food and Beverage | $19,125.61 | 268 |
| Honoraria | $8,000.00 | 2 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BOB GENG
NPI 1356570758 · CMS profile ID 288980
Allopathic & Osteopathic Physicians / Allergy & Immunology
SAN DIEGO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BOB GENG, NPI 1356570758, CMS profile ID 288980. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). BOB GENG, NPI 1356570758, CMS profile ID 288980. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- BOB GENG, NPI 1356570758, CMS profile ID 288980, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 12; records 51–100 of 553 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356570758?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
553 matching records · $565,906.48 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 553.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| BioCryst US Sales Co., LLC | $485.79 | 11/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117480060 | CMS |
| BioCryst US Sales Co., LLC | $124.99 | 11/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117480884 | CMS |
| BioCryst US Sales Co., LLC | $776.20 | 11/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117474336 | CMS |
| BioCryst US Sales Co., LLC | $2,410.16 | 11/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117475950 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 11/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116703866 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $659.74 | 11/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137553441 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,705.46 | 11/06/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114054335 | CMS |
| GC Biopharma USA, Inc. | $23.07 | 11/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155403200 | CMS |
| Pharming Healthcare, Inc. | $19.02 | 11/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132148760 | CMS |
| PFIZER INC. | $21.65 | 10/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132105714 | CMS |
| Grifols USA, LLC | $20.79 | 10/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124734231 | CMS |
| PFIZER INC. | $3,000.00 | 10/28/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131623603 | CMS |
| Blueprint Medicines Corporation | $55.18 | 10/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147452365 | CMS |
| Novartis Pharmaceuticals Corporation | $35.09 | 10/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086906103 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $58.39 | 10/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137553439 | CMS |
| Novartis Pharmaceuticals Corporation | $90.71 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086906113 | CMS |
| BioCryst US Sales Co., LLC | $75.13 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117469417 | CMS |
| Regeneron Healthcare Solutions, Inc. | $94.45 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114054333 | CMS |
| ABBVIE INC. | $2,875.00 | 10/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103151477 | CMS |
| ABBVIE INC. | $2,875.00 | 10/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103151479 | CMS |
| ABBVIE INC. | $4,025.00 | 10/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103151481 | CMS |
| ADMA BioManufacturing LLC | $7.00 | 10/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149638674 | CMS |
| ADMA BioManufacturing LLC | $134.42 | 10/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639566 | CMS |
| GENZYME CORPORATION | $25.62 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828296 | CMS |
| GlaxoSmithKline, LLC. | $491.00 | 10/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115980838 | CMS |
| ADMA BioManufacturing LLC | $150.00 | 10/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639924 | CMS |
| ADMA BioManufacturing LLC | $699.10 | 10/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639926 | CMS |
| ADMA BioManufacturing LLC | $1,616.00 | 10/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639928 | CMS |
| ADMA BioManufacturing LLC | $635.00 | 10/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639930 | CMS |
| ADMA BioManufacturing LLC | $5,000.00 | 10/17/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1149639932 | CMS |
| Pharming Healthcare, Inc. | $13.84 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132148755 | CMS |
| GENZYME CORPORATION | $2,399.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828316 | CMS |
| GENZYME CORPORATION | $18.98 | 10/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828324 | CMS |
| GENZYME CORPORATION | $2,399.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828326 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116377564 | CMS |
| GlaxoSmithKline, LLC. | $1,950.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116455225 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116467778 | CMS |
| GlaxoSmithKline, LLC. | $3,900.00 | 10/11/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116727718 | CMS |
| GENZYME CORPORATION | $130.32 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828330 | CMS |
| GENZYME CORPORATION | $6,396.00 | 10/10/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828332 | CMS |
| GENZYME CORPORATION | $316.08 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828334 | CMS |
| GENZYME CORPORATION | $749.67 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828336 | CMS |
| GENZYME CORPORATION | $1,764.89 | 10/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828338 | CMS |
| GENZYME CORPORATION | $9,812.00 | 10/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139828348 | CMS |
| Pharming Healthcare, Inc. | $23.90 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1132148749 | CMS |
| GlaxoSmithKline, LLC. | $83.75 | 10/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116099275 | CMS |
| GlaxoSmithKline, LLC. | $918.00 | 10/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116531394 | CMS |
| GlaxoSmithKline, LLC. | $107.20 | 10/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116557297 | CMS |
| GlaxoSmithKline, LLC. | $51.59 | 10/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116634738 | CMS |
| GlaxoSmithKline, LLC. | $13.39 | 10/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116724376 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $33,050.55 | 6 |
| PY2025 | Principal investigator | $909,096.20 | 17 |
| PY2024 | Recipient | $46,530.00 | 7 |
| PY2024 | Principal investigator | $444,485.66 | 19 |
| PY2023 | Recipient | $49,420.00 | 8 |
| PY2023 | Principal investigator | $634,787.69 | 14 |
| PY2022 | Recipient | $6,226.25 | 3 |
| PY2022 | Principal investigator | $545,288.26 | 1 |
| PY2021 | Recipient | $2,670.00 | 3 |
| PY2020 | Recipient | $6,499.28 | 7 |
| PY2020 | Principal investigator | $29,930.16 | 2 |
| PY2019 | Recipient | $355.10 | 1 |
| PY2019 | Principal investigator | $99,839.39 | 18 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
23 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $46,625.00 | 12/12/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER APC | Real World Experience and Pharmacokinetics of IG-Naive Immunodeficiency Patients Starting Cuvitru | No dispute reported | 06/30/2026 | 1223289702 |
| Principal investigator 1 | GENZYME CORPORATION | $43,813.00 | 11/10/2025 | Non-covered Recipient Entity Allergy And Asthma Medical Group And Research Center, Apc | Mechanism of Action and Immunomodulatory Effects of Dupilumab on Chronic Rhinosinusitis with Nasal Polyposis | No dispute reported | 06/30/2026 | 1226145362 |
| Principal investigator 1 | Lilly USA, LLC | $25,000.00 | 11/03/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER APC | Not supplied | No dispute reported | 06/30/2026 | 1187872539 |
| Principal investigator 1 | Amgen Inc. | $15,629.21 | 10/24/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER | A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) | No dispute reported | 06/30/2026 | 1246638959 |
| Recipient | LEO Pharma Inc. | $25,000.00 | 10/15/2025 | Covered Recipient Physician | CHARACTERIZATION OF UNMET NEED FOR TARGETED PRECISION MEDICATION IN ATOPIC DERMATITIS DUE TO INADEQUATE OR POOR RESPONSE TO DUPILUMAB | No dispute reported | 06/30/2026 | 1251994446 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $56,100.00 | 09/30/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER | A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged =6 to <18 Years With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1184244419 |
| Recipient | Amgen Inc. | $2,030.55 | 09/22/2025 | Covered Recipient Physician | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) | No dispute reported | 06/30/2026 | 1246636966 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $14,869.00 | 08/28/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER, APC | A Multicentre,Randomised,Double Blind,Parallel Group,Placebo Controlled,52 week,Phase 3,Efficacy and Safety Study of Tezepelumab in 5 to 12 Year Old Children with Severe Uncontrolled Asthma HORIZON | No dispute reported | 06/30/2026 | 1185553924 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $28,050.00 | 07/29/2025 | Non-covered Recipient Entity ALLERGY & ASTHMA MEDICAL GROUP AND RESEARCH CENTER | A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged =6 to <18 Years With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1184221354 |
| Principal investigator 1 | GENZYME CORPORATION | $345,249.18 | 06/05/2025 | Non-covered Recipient Entity Allergy And Asthma Medical Group And Research Center, Apc | ORIGINS: Deciphering the immunopathogenesis of atopic dermatitis, using spatial single-cell transcriptomics to identify key pathways and targetable mediators involved in the disease trajectory | No dispute reported | 06/30/2026 | 1226145326 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $12,151.00 | 05/09/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | a twelfeweek randomized doubleblind phase four study evaluating the effect of airsupra compared to albuterol administered as needed on changes in airway inflammation symptoms and rescue therapy utilization in adults with mild asthma darwin | No dispute reported | 06/30/2026 | 1185553928 |
| Principal investigator 1 | Incyte Corporation | $32,700.00 | 05/07/2025 | Non-covered Recipient Entity Allergy & Asthma Medical Grp and Rch Ctr | A Quality Improvement Study - Assessing Total Steroid Burden for Patients with Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240501637 |
| Principal investigator 1 | Incyte Corporation | $32,700.00 | 05/07/2025 | Non-covered Recipient Entity Allergy & Asthma Medical Grp and Rch Ctr | A Quality Improvement Study - Assessing Total Steroid Burden for Patients with Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240501641 |
| Recipient | PFIZER INC. | $3,200.00 | 04/26/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228828987 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $21,000.00 | 04/23/2025 | Non-covered Recipient Entity Allergy And Asthma Medical Group And Research Center, Apc | Chronic Rhinosinusitis without Nasal Polyps Screening and Prospective Testing | No dispute reported | 06/30/2026 | 1244167845 |
| Principal investigator 1 | Eli Lilly and Company | $1,024.95 | 03/20/2025 | Non-covered Recipient Entity MEETING PROTOCOL WORLDWIDE LP | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187884934 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $97,721.85 | 03/07/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL | No dispute reported | 06/30/2026 | 1185553926 |
| Recipient | PFIZER INC. | $940.00 | 03/07/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228828404 |
| Recipient | PFIZER INC. | $940.00 | 01/30/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228828981 |
| Recipient | PFIZER INC. | $940.00 | 01/30/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228829593 |
| Principal investigator 1 | Eli Lilly and Company | $49,588.03 | 01/15/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS | No dispute reported | 06/30/2026 | 1187880647 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $85,638.53 | 01/03/2025 | Non-covered Recipient Entity CRN CLINICAL RESEARCH NETWORK | A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma | No dispute reported | 06/30/2026 | 1185553922 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $1,236.45 | 01/01/2025 | Non-covered Recipient Entity ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER | A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled | No dispute reported | 06/30/2026 | 1190309740 |